+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Genital Herpes - Pipeline Insight, 2020

  • ID: 4989326
  • Drug Pipelines
  • February 2020
  • Region: Global
  • 106 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Immune Design
  • Sanofi Pasteur
  • United BioPharma
  • MORE
Genital Herpes Overview

Genital Herpes Pipeline Insight, 2020 report outlays comprehensive insights of present clinical development scenario and growth prospects across the Genital Herpes market. A detailed picture of the Genital Herpes pipeline landscape is provided, which includes the disease overview and Genital Herpes treatment guidelines. The assessment part of the report embraces in-depth Genital Herpes commercial assessment and clinical assessment of the Genital Herpes pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Genital Herpes collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Genital Herpes of pipeline development activities

The report provides insights into:
  • All of the companies that are developing therapies for the treatment of Genital Herpes with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Genital Herpes treatment.
  • Genital Herpes key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Genital Herpes market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.

Genital Herpes Analytical Perspective

In-depth Genital Herpes Commercial Assessment Of Products

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

Genital Herpes Clinical Assessment Of Products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report
  • The Genital Herpes report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Genital Herpes across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Genital Herpes therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Genital Herpes research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Genital Herpes .
Report Highlights
  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Genital Herpes .
  • In the coming years, the Genital Herpes market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Genital Herpes R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Genital Herpes treatment market. Several potential therapies for Genital Herpes are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Genital Herpes market size in the coming years.
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Genital Herpes ) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Key Questions
  • What are the current options for Genital Herpes treatment?
  • How many companies are developing therapies for the treatment of Genital Herpes?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Genital Herpes?
  • How many Genital Herpes emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Genital Herpes?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Genital Herpes market?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Genital Herpes?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Genital Herpes therapies?
  • What are the clinical studies going on for Genital Herpes and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for Genital Herpes?
  • How many patents are granted and pending for the emerging therapies for the treatment of Genital Herpes?


This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Immune Design
  • Sanofi Pasteur
  • United BioPharma
  • MORE
1. Report Introduction

2. Genital Herpes
2.1. Overview
2.2. History
2.3. Genital Herpes Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Genital Herpes Diagnosis
2.6.1. Diagnostic Guidelines

3. Genital Herpes Current Treatment Patterns
3.1. Genital Herpes Treatment Guidelines

4. Genital Herpes - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Genital Herpes companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Genital Herpes Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Genital Herpes Acquisition Analysis

5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target

6. Genital Herpes Late Stage Products (Phase-III)

7. Genital Herpes Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Genital Herpes Discontinued Products

13. Genital Herpes Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table

14. Genital Herpes Key Companies

15. Genital Herpes Key Products

16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation

17. Genital Herpes Unmet Needs

18. Genital Herpes Future Perspectives

19. Genital Herpes Analyst Review

20. Appendix

21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Sanofi Pasteur
  • Immune Design
  • United BioPharma
  • Heidelberg ImmunoTherapeutics GmbH
Note: Product cover images may vary from those shown
Adroll
adroll